Helicobacter. 2019;24(6):e12660.
Primary and secondary antibiotic resistance of Helicobacter pylori in Korea from 2003 to 2018.
제1저자 이주엽 · 교신저자 김나영
소속 (4)
- Department of Internal Medicine, Seoul National University Bundang Hospital, Seoungnam, South Korea.
- Department of Internal Medicine, Keimyung University School of Medicine, Daegu, South Korea.
- Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, Seoul, South Korea.
- Department of Internal Medicine, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Changwon, South Korea.
Abstract
BACKGROUND Antimicrobial resistance of Helicobacter pylori (H pylori) affects the efficacy of eradication therapy. The aim of this study was to estimate the prevalence of primary and secondary resistance of H pylori isolates to antibiotics in Korea.
METHODS The present study was performed from 2003 to 2018. Primary resistance was evaluated in 591 patients without any history of eradication and secondary resistance in 149 patients from whom Helicobacter pylori was cultured after failure of eradication. A minimal inhibitory concentration test was performed for amoxicillin, clarithromycin, metronidazole, tetracycline, levofloxacin, and rifabutin using the agar dilution method.
RESULTS An increase in the primary resistance rate was found in clarithromycin (P < .001), metronidazole (P < .001), and both levofloxacin (P < .001) during the study period. The primary resistance rates of amoxicillin and tetracycline were low and stable during the study period. The secondary resistance rate significantly increased in metronidazole and levofloxacin (P = .022 and .039, respectively).
CONCLUSIONS The primary and secondary resistance rates of clarithromycin, metronidazole, and levofloxacin for Helicobacter pylori in Korea were high and increased over time. However, the primary and secondary resistance rates of amoxicillin and tetracycline were low and stable over time. These results will help in selecting effective eradication regimens of H pylori in Korea in the future.
© 2019 John Wiley & Sons Ltd.
Keywords
Helicobacter pyloriantibioticsprevalenceresistance
그 밖의 정보
- 출판 형태
- Journal Article
- 저널
- Helicobacter · eISSN 1523-5378
- 전자 출판
- 2019-09-11
- MeSH
- Adult · Aged · Amoxicillin / pharmacology · Anti-Bacterial Agents / pharmacology · Clarithromycin / pharmacology · Drug Resistance, Multiple, Bacterial* · Female · Helicobacter Infections / drug therapy / microbiology · Helicobacter pylori / classification / drug effects / genetics / isolation & purification · Humans · Levofloxacin / pharmacology · Male · Microbial Sensitivity Tests · Middle Aged · Republic of Korea · Young Adult
- Substances
- Anti-Bacterial Agents · Levofloxacin · Amoxicillin · Clarithromycin
- 연구비
- National Research Foundation of Korea (NRF) grant for the Global Core Research Center (GCRC), funded by the Korean government (MSIP) 2011-0030001 · National Research Foundation of Korea (NRF) Grant funded by the Korea Government (MSIP) 2014R1A5A2010008
- 참고문헌
- 49편